EUVIMEDEUVIMED entdecken
Open Access

Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors

Paul Johannet iD, Somer Abdelfattah, Callahan Wilde, Shrey Patel, Henry Walch iD, Benoit Rousseau iD, Guillem Argiles iD, Oliver Artz iD, Miteshkumar Patel, Andrea Arfe iD, Andrea Cercek iD, Rona Yaeger iD und 4 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Paul Johannet und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering, New York, NY. Hauptthemen laut MEDLINE: GTP-Binding Protein alpha Subunits, Gs, Chromogranins, Mutation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The molecular drivers underlying mucinous tumor pathogenicity are poorly understood. GNAS mutations predict metastatic burden and treatment resistance in mucinous appendiceal adenocarcinoma. We investigated the pan-cancer clinicopathologic relevance of GNAS variants. METHODS We assessed 58,043 patients with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT)–sequenced solid tumors to identify oncogenic variants, including GNAS , associated with mucinous tumor phenotype. We then performed comprehensive molecular analyses to compare GNAS- mutant (mut) and wild-type tumors across cancers. Gene expression patterns associated with GNAS- mut tumors were assessed in a The Cancer Genome Atlas cohort. Associations between GNAS variant status and peritoneal metastasis, first-line systemic therapy response, progression-free survival (PFS), and overall survival (OS) were determined using a propensity-matched subcohort of patients with metastatic disease. RESULTS Mucinous tumors were enriched for oncogenic GNAS variants. GNAS was mutated in >1% of small bowel, cervical, colorectal, pancreatic, esophagogastric, hepatobiliary, and GI neuroendocrine cancers. Across these cancers, GNAS- mut tumors exhibited a generally conserved C-to-T mutation-high, aneuploidy-low molecular profile with co-occurring prevalent KRAS variants (65% of GNAS-mut tumors) and fewer TP53 alterations. GNAS- mut tumors exhibited recurrently comutated alternative tumor suppressors ( RBM10 , INPPL1 ) and upregulation of MAPK and cell surface modulators. GNAS- mut tumors demonstrate an increased prevalence of peritoneal metastases (odds ratio [OR], 1.7 [95% CI, 1.1 to 2.5]; P = .006), worse response to first-line systemic therapy (OR, 2.2 [95% CI, 1.3 to 3.8]; P = .003), and shorter PFS (median, 5.6 v 7.0 months; P = .047). In a multivariable analysis, GNAS mutated status was independently prognostic of worse OS (hazard ratio, 1.25 [95% CI, 1.01 to 1.56]; adjusted P = .04). CONCLUSION Across the assessed cancers, GNAS- mut tumors exhibit a conserved molecular and clinical phenotype defined by mucinous tumor status, increased peritoneal metastasis, poor response to first-line systemic therapy, and worse survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GTP-Binding Protein alpha Subunits, GsChromograninsMutationHumansMaleFemaleMiddle AgedAgedAdenocarcinoma, MucinousNeoplasmsBiomarkers, Tumor

Substanzen

GTP-Binding Protein alpha Subunits, GsGNAS protein, humanChromograninsBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering, New York, NY.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Paul Johannet, Henry Walch, Benoit Rousseau, Guillem Argiles, Oliver Artz, Andrea Arfe, Andrea Cercek, Rona Yaeger, Karuna Ganesh, Nikolaus Schultz, Luis A Diaz, Michael B Foote

Förderung

  • NCI NIH HHS

Zitieren

APA

Johannet, P., Abdelfattah, S., Wilde, C., Patel, S., Walch, H., Rousseau, B., Argiles, G., Artz, O., Patel, M., Arfe, A., Cercek, A., Yaeger, R., Ganesh, K., Schultz, N., Diaz, L. A., & Foote, M. B. (2024). Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00186

Vancouver

Johannet P, Abdelfattah S, Wilde C, Patel S, Walch H, Rousseau B, et al. Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00186

BibTeX
@article{Johannet2024,
  author = {Johannet, Paul and Abdelfattah, Somer and Wilde, Callahan and Patel, Shrey and Walch, Henry and Rousseau, Benoit and Argiles, Guillem and Artz, Oliver and Patel, Miteshkumar and Arfe, Andrea and Cercek, Andrea and Yaeger, Rona and Ganesh, Karuna and Schultz, Nikolaus and Diaz, Luis A and Foote, Michael B},
  title = {Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00186}
}
Kostenlos starten →